Increasing Efforts Toward Preventing and Treating Life-Threatening Animal Diseases Acting as Catalyst for Veterinary Anti-infective Market Growth: Fact.MR Report
Increasing Efforts Toward Preventing and Treating Life-Threatening Animal Diseases Acting as Catalyst for Veterinary Anti-infective Market Growth: Fact.MR Report
According to a new industry report released by Fact.MR, the global veterinary anti-infective marketis estimated at US$ 5.03 billion in 2024 and is forecasted to reach US$ 7.47 billion by the end of 2034.
Anti-infectives are medications that help prevent the spread or transmission of diseases. Moreover, veterinary anti-infectives are healthcare products that prevent or treat the spread of infectious diseases between humans and animals.
Growing emphasis on the prevention and treatment of fatal animal diseases are key market indicators for veterinary antibiotics. The veterinary anti-infective market is expanding at a moderate pace due to several factors, including the rising prevalence of foodborne and zoonotic illnesses, the popularity of pets, and the expansion of animal healthcare research and development.
Increasing concerns about pet health and the rising incidence of bacterial infections, especially in dogs, along with an increase in pet adoption are expected to contribute to the steady demand growth for veterinary anti-infective solution.
For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=10182
Key Takeaways from Market Study:
“Rise in foodborne infections, often originating from animals, is posing a threat to human health. This is a significant driver boosting demand for veterinary anti-infective medications,” says a Fact.MR analyst.
Leading Players Driving Innovation in the Veterinary Anti-Infective Market
Neogen Corporation; Phibro Animal Health Corporation; Sanofi (Merial Animal Health); Vetoquinol S.A.; Virbac S.A.; Zoetis, Inc.; Boehringer Ingelheim GmbH; Ceva Santé Animale; Indian Immunologicals Limited; Intas Pharmaceuticals Limited; Norbrook Laboratories Limited; Ashish Life Science Private; Zydus Animal Health Limited.
Increasing Government Efforts Promoting Veterinary Health Services in Hospitals and Clinics
Growth of the market for veterinary anti-infectives is driven by stricter regulations enacted to prevent animal diseases and increased awareness of veterinary healthcare. Government initiatives to encourage veterinary services in hospitals and clinics are driving market growth.
Rising demand for premium meat in the United States means that diseases are effectively avoided in cattle and treated when they do occur. With consumers growing more health conscious, it is imperative to ensure the welfare of farm animals. To maintain animal health and food safety, veterinary anti-infectives are crucial.
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=10182
Veterinary Anti-Infective Industry News:
More Valuable Insights on Offer:
Fact.MR, in its new offering, presents an unbiased analysis of the veterinary anti-infective market for 2019 to 2023 and forecast statistics for 2024 to 2034.
The study divulges the veterinary anti-infective market based on species (livestock animals, companion animals), drug class (antimicrobial agents, antiviral agents, antifungal agents, antiparasitic agents), mode of administration (oral, parenteral, topical), and distribution channel (veterinary hospitals, veterinary clinics, pharmacies),across seven major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and MEA).
Check out More Related Studies Published by Fact.MR:
The global contraceptives market is expected to grow from US$ 33 billion in 2023 to US$ 62 billion by 2033, at a 6.5% CAGR.
The insulin delivery devices market is set to expand from US$ 16.8 billion in 2023 to US$ 33.1 billion by 2033, growing at a 7% CAGR.
The self-care medical devices market, valued at US$ 13 billion in 2020, is projected to reach US$ 20 billion by 2031 at a 6% CAGR, with blood pressure monitors growing at 8% and holter monitors at 5%.
The global nizatidine market is anticipated to rise from US$ 5.1 billion in 2021 to US$ 12.2 billion by 2031, expanding at a 9% CAGR.
The fluoroscopy equipment market, valued at US$ 1.9 billion in 2022, is expected to reach US$ 3.5 billion by 2031, growing at a 6% CAGR.
The phototherapy devices market is expected to grow at a 7% CAGR, exceeding US$ 1.5 billion by 2031, while LED-based devices will expand at a 6% CAGR from 2021 to 2031.
The kidney cancer diagnostics market is expected to grow at a 7% CAGR from 2022 to 2032, reaching a valuation of US$ 800 million in 2022.
The global breast cancer diagnostics market, valued at US$ 5,977 million in 2025, is forecasted to reach US$ 12,451 million by 2035, growing at a 6.9% CAGR.
CAGR stands for Compound Annual Growth Rate, a measure used to calculate the mean annual growth rate of an investment over a specified time period.
Explore more articles in the Research Reports category
